The standard framing of Parkinson's disease management focuses on symptom control: dopaminergic medications, adjusted over time as the disease progresses, manage the motor symptoms and allow people to maintain function. This is the correct approach to symptomatic management. But it leaves unaddressed the question of whether anything can slow the underlying neurodegeneration that drives the progression of the disease, the continued loss of dopaminergic neurons in the substantia nigra that makes medication management progressively more complex over years. No currently approved pharmacological treatment has been shown to modify Parkinson's disease progression. The evidence that vigorous exercise may have a disease-modifying effect is therefore of extraordinary clinical importance, and the degree to which this evidence has penetrated clinical practice and patient awareness remains limited. For adults with Parkinson's on the Isle of Man, understanding this evidence and its practical implications may be among the most valuable health information available to them.
The Neuroplasticity Evidence: Exercise Changes Parkinson's Brains
The concept that exercise produces neuroplastic changes in the brain, altering the structure and function of neural circuits in response to the demands placed on them, is well-established in general neuroscience. In the context of Parkinson's, the key question is whether exercise can produce neuroplastic changes specifically in the dopaminergic and motor circuits affected by the disease. Fisher and colleagues published landmark research in 2008 demonstrating that high-intensity exercise in early Parkinson's patients produced measurable changes in cortical motor excitability, measured by transcranial magnetic stimulation, alongside improvements in motor performance. These changes in cortical excitability are consistent with exercise-induced neuroplasticity in the motor cortex, not merely peripheral muscle conditioning.
Animal research using rodent models of Parkinson's disease has examined the mechanistic basis of exercise neuroprotection with considerably more biological detail than is possible in human studies. Studies using 6-OHDA and MPTP rodent models of dopaminergic neuron loss have consistently found that forced or voluntary exercise protects against dopaminergic neuron loss, preserves dopamine and its metabolites in the striatum, and maintains nigrostriatal dopaminergic function compared with sedentary controls given the same neurotoxic insult. The proposed mechanisms include exercise-induced increases in BDNF, which has neuroprotective effects on dopaminergic neurons; increased dopamine synthesis and release; reduced neuroinflammation; and enhanced mitochondrial function in substantia nigra neurons.
Human Clinical Trial Evidence for Exercise-Induced Improvement
Translating the animal neuroprotection findings to human clinical trials is methodologically challenging, because measuring dopaminergic neuron protection in living humans is not straightforward. However, several important human trials have demonstrated improvements in Parkinson's motor symptoms beyond what can be explained by peripheral muscle adaptation alone, suggesting central neuroplastic effects. Corcos and colleagues' two-year resistance training trial showed significant improvements in UPDRS motor scores, the standard clinical measure of Parkinson's motor symptom severity, at 24 months, with the exercise group performing significantly better than the stretching control group. This is a clinically meaningful finding: UPDRS improvements at 24 months in a progressive disease suggest that exercise is doing something beyond symptomatic management.
The SPARX trials, examining forced-intensity treadmill exercise in Parkinson's, have produced the strongest human evidence for exercise as a potential disease modifier to date. Allen and colleagues, reporting Phase 2 results in JAMA Neurology in 2018, found that high-intensity treadmill training in early Parkinson's produced significantly less UPDRS motor symptom deterioration at six months compared with moderate or low-intensity exercise, consistent with a dose-dependent neuroprotective effect. The biological plausibility is supported by the animal data, and the Phase 3 trial needed to confirm disease modification is ongoing. For practical purposes, the existing evidence strongly supports prescribing vigorous exercise as early as possible after diagnosis, not as an adjunct for those who want to be active but as a clinical intervention with potential disease-modifying properties.
Practical Implications: What Type and Intensity of Exercise
The exercise intensity question is important. The animal and human evidence consistently points towards high-intensity or vigorous exercise producing greater benefits than low-intensity or gentle activity. Walking at a comfortable pace, while beneficial for general health and cardiovascular fitness, is unlikely to produce the neuroplastic stimulus that the neuroprotection hypothesis requires. The forced-intensity treadmill protocols used in the SPARX trials, and the high-intensity resistance training used by Corcos, both push patients to efforts that most would find moderately to quite difficult, significantly above the intensity of typical Parkinson's exercise recommendations.
The practical challenge for many Parkinson's patients is that fatigue is a significant symptom of the disease and that achieving high exercise intensities is genuinely difficult. This is where structured supervised exercise with professional support, and potentially EMS as a supplement for muscle activation on days when voluntary effort is limited, offers the best practical route to achieving the exercise doses associated with neuroplastic benefit. Adults with Parkinson's on the Isle of Man who are in the early to mid stages of the disease and have adequate cardiovascular capacity should be encouraged to pursue vigorous exercise, supervised where necessary for safety, as a priority clinical intervention alongside their medication.
Integrating the Evidence into an Isle of Man Parkinson's Programme
A comprehensive exercise programme for Parkinson's on the Isle of Man should include elements that address the multiple benefits identified in the research: resistance training for muscle preservation and UPDRS motor improvement; high-intensity aerobic exercise for potential neuroprotection; EMS for muscle activation maintenance on limited-capacity days; balance and gait training for falls prevention; and flexibility and posture work for the axial rigidity and postural flexion of advancing disease. This is a substantial programme, and the practical challenge of sustaining it through the fatigue and motivational challenges of a progressive neurological condition requires professional support, family involvement, and a care structure that prioritises exercise as a clinical treatment.
At Zhen Wellness on the Isle of Man, we work with individuals who have Parkinson's disease as part of our broader longevity and rehabilitation practice, providing supervised EMS, functional movement training, and nutritional support that complements the neurological management provided by the clinical team. We communicate openly with the treating neurologist and Parkinson's nurse, and we are committed to the principle that exercise should be treated as a medicine in Parkinson's disease, dosed appropriately, supervised safely, and progressed over time with the same evidence-based rigour as any other intervention.
- No approved pharmacological treatment modifies Parkinson's disease progression; exercise is the leading candidate for disease modification
- Fisher (2008) shows high-intensity exercise produces measurable cortical motor excitability changes in early Parkinson's
- Animal models consistently show exercise protects dopaminergic neurons from neurotoxic insult through BDNF and other mechanisms
- Corcos (2013) two-year RCT: UPDRS motor score improvement with resistance training vs stretching at 24 months
- SPARX trials show dose-dependent benefit of exercise intensity: high-intensity training produces less disease progression
- Fatigue limits high-intensity exercise in Parkinson's; supervised programmes and EMS on limited days optimise the achievable dose
- Exercise should be treated as a clinical medicine in Parkinson's disease, not an optional lifestyle recommendation
Sources
- Ahlskog, J.E. (2011). Does vigorous exercise have a neuroprotective effect in Parkinson disease? Neurology, 77(3), 288-294.
- Fisher, B.E., et al. (2008). The effect of exercise training in improving motor performance. European Journal of Neuroscience, 35(12), 1659-1668.
- Corcos, D.M., et al. (2013). A two-year randomized controlled trial of progressive resistance exercise for Parkinson's disease. Movement Disorders, 28(9), 1230-1240.
- Bloem, B.R., et al. (2021). Parkinson's disease. Lancet, 397(10291), 2284-2303.
- Poewe, W., et al. (2017). Parkinson disease. Nature Reviews Disease Primers, 3, 17013.